Galectin Therap

Q2 FY2026 EarningsGALT.US reported Q2 FY2026 results with a net loss of $9.1M, underperforming the consensus mean expectation of a $6.1M loss. Revenue remained at zero in-line with expectations as a clinical-stage biotech. EPS GAAP was -$0.14, missing the -$0.09 consensus due to higher-than-expected non-cash interest and derivative fair value adjustments. However, a significant post-quarter debt-to-equity conversion of $105.8M by the Chairman materially improved the balance sheet, though going concern risks persist through June 2027.